FFA
DNLI icon

Farther Finance Advisors’s Denali Therapeutics DNLI Stock Holding History

Farther Finance Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Sell
504
-33
-6% -$772 ﹤0.01% 4593
2026
Q2 		$13.8K Buy
537
+282
+111% +$5.79K ﹤0.01% 4221
2026
Q1 		$5.02K Buy
255
+53
+26% +$1.05K ﹤0.01% 4491
2025
Q4 		$3.33K Buy
202
+75
+59% +$1.27K ﹤0.01% 4489
2025
Q3 		$1.84K Buy
127
+20
+19% +$287 ﹤0.01% 4165
2025
Q2 		$1.5K Buy
107
+100
+1,429% +$1.41K ﹤0.01% 3793
2025
Q1 		$86 Sell
7
-28
-80% -$536 ﹤0.01% 4085
2024
Q4 		$713 Sell
35
-72
-67% -$1.84K ﹤0.01% 3355
2024
Q3 		$3.13K Buy
107
+27
+34% +$669 ﹤0.01% 2828
2024
Q2 		$1.76K Buy
80
+45
+129% +$864 ﹤0.01% 2844
2024
Q1 		$720 Sell
35
-49
-58% -$921 ﹤0.01% 2899
2023
Q4 		$1.8K Buy
+84
New +$1.66K ﹤0.01% 2475

Other funds holding DNLI

BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors's DNLI Position: Q3 2026 in Review

Farther Finance Advisors reduced its Denali Therapeutics (DNLI) stake by 6.1% in Q3 2026, selling an estimated $772 and leaving 504 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4593.

Farther Finance Advisors first reported a position in DNLI in Q4 2023 and has held it in 12 quarters since. The position peaked at $13.8K in Q2 2026. 5 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Farther Finance Advisors held 504 shares of Denali Therapeutics worth $10.4K as of Q3 2026.
  • Farther Finance Advisors sold 33 Denali Therapeutics shares in Q3 2026, an estimated $772.
  • Denali Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4593 holding.
  • Farther Finance Advisors first reported a position in Denali Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Denali Therapeutics position peaked at $13.8K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.